Clinical trials: Ulcerative Colitis (UC)
Ulcerative Colitis
Anal Manometry Examination in Patients With Ulcerative Colitis
Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), are chronic immune-related diseases.
- Trial name
- NCT05488041
- Testing
- Performing anorectal manometry
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Assaf-Harofeh Medical Center
Ulcerative Colitis (UC)
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis
A study to investigate the safety, tolerability, and pharmacokinetics (PK) of ONO-6414 orally in healthy adult participants and in patients with active ulcerative colitis (UC).
- Trial name
- NCT07749768
- Testing
- ONO-6414
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Crohn Disease (CD), Ulcerative Colitis (UC)
TIDHI Mental Health in IBD Patients Study
The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1.
- Conditions
- Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD)
- Trial name
- NCT07013578
- Testing
- Healing Circuits™ sessions, self-directed Healing Circuits™ curriculum
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- TIDHI Innovation Inc.
Ulcerative Colitis
Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
To evaluate the real-life effect after 1 year of adalimumab treatment on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.
- Trial name
- UCanADA (NCT02506179)
- Where
- 23 sites in Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Ulcerative Colitis (UC), Crohns Disease
Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors.
- Trial name
- NCT07431983
- Where
- 2 sites in India
- Volunteers
- 200 people
- Sponsor
- Asian Institute of Gastroenterology, India
Crohn's Disease (CD), Ulcerative Colitis (UC)
Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis
This single-center, retrospective study aims to evaluate the effectiveness and safety of upadacitinib (UPA) in Asian pediatric patients with refractory Crohn's disease (CD) and elderly patients with refractory ulcerative colitis…
- Conditions
- Crohn's Disease (CD), Ulcerative Colitis (UC), Refractory Crohn's Disease, Refractory Ulcerative Colitis
- Trial name
- UPA-AGE (NCT06922331)
- Testing
- Upadacitinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Crohn, Ulcerative Colitis (UC)
Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.
Inflammatory Bowel Diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, disabling conditions affecting young adults, marked by flare-ups and remissions.
- Conditions
- Crohn, Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease)
- Trial name
- SUIVITHEQUE2 (NCT07172945)
- Testing
- Blood, fecal, saliva, intestinal content samples and biopsies
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ulcerative Colitis (UC), Indeterminate Colitis
CEDUR - German IBD Registry
The CEDUR registry systematically collects real-world data on inflammatory bowel disease (IBD) patients in Germany. The registry aims to assess quality of care, disease activity, treatment effectiveness, safety, and…
- Conditions
- Ulcerative Colitis (UC), Indeterminate Colitis, Crohn Disease (CD)
- Trial name
- CEDUR (NCT07319442)
- Where
- Germany
- Volunteers
- 10,000 people
- Sponsor
- ImmunoRegister gUG
Ulcerative Colitis
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
To describe the effectiveness, treatment patterns, quality of life, and safety of participants with moderately or severely active UC treated with filgotinib in a real-world setting.
- Trial name
- GALOCEAN (NCT05817942)
- Testing
- Filgotinib
- Where
- 81 sites in Austria, Belgium and 8 more
- Volunteers
- 509 people
- Sponsor
- Alfasigma S.p.A.
Ulcerative Colitis (UC)
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
Ulcerative colitis (UC) is a chronic bowel disease. It causes inflammation of the rectum and sometimes the colon. This disease can also affect other parts of the body. It can be very difficult to live with on a daily basis.
- Trial name
- STARTER (NCT07576452)
- Testing
- 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab
- Where
- 13 sites in France
- Volunteers
- 240 people
- Sponsor
- University Hospital, Clermont-Ferrand
Ulcerative Colitis
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
This is a multi-center, randomized, parallel arm, double-blind study with approximately 750 participants with moderately to severely active Colitis Ulcerosa randomized to receive either PB016 or Entyvio®
- Trial name
- UCESIVE (NCT05771155)
- Testing
- Intravenous (IV) infusions
- Where
- Georgia
- Volunteers
- 750 people
- Sponsor
- Polpharma Biologics S.A.
Crohn's Disease, Ulcerative Colitis
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel.
- Trial name
- NCT06764615
- Testing
- Zasocitinib
- Where
- 16 sites in United States, China and 6 more
- Volunteers
- 192 people
- Sponsor
- Takeda
Colitis, Ulcerative
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely…
- Trial name
- LAUREL (NCT02165215)
- Testing
- Etrolizumab
- Where
- 104 sites in United States, Brazil and 13 more
- Volunteers
- 359 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
Multi-interventional Program to Reduce Chronic Ileoanal Pouch Leaks in UC
The objective of this quality improvement project is to increase the one year anastomotic integrity rate in patients having had completion proctectomy and pouch reconstruction for Ulcerative Colitis by the routine and quality…
- Trial name
- MIRACLE (NCT04939025)
- Testing
- Multi-interventional program
- Volunteers
- 50 people
- Sponsor
- London North West Healthcare NHS Trust
Ulcerative Colitis (UC), Inflammatory Bowel Disease
Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han Donors
This study is a randomized clinical trial evaluating fecal microbiota transplantation (FMT) for ulcerative colitis (UC) using healthy donors from two ethnic groups in Yunnan, China.
- Trial name
- NCT07814456
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Kunming Medical University
Ulcerative Colitis
Real World Study Of The Clinical Profile And Treatment Outcomes Of Advanced Therapies For Ulcerative Colitis In Portugal
This study aims to characterize the Portuguese population of patients with moderate-to-severe UC receiving advanced therapies, by describing clinical and sociodemographic characteristics, and remission outcomes .
- Trial name
- READ-UC (NCT04156672)
- Sponsor
- Pfizer
Ulcerative Colitis (UC)
An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis
A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.
- Trial name
- NCT07459686
- Testing
- Velsipity
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Inflammatory Bowel Disease, Crohn's Disease
SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins
This study aims to investigate the role of non-genetic factors in the pathogenesis of inflammatory bowel disease.An exploratory study to investigate differences between the epigenome, microbiota and functional immunology in twins…
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT02383953
- Where
- United Kingdom
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- St Stephens Aids Trust
Inflammatory Bowel Diseases, Crohn Disease
Validation and Clinical Impact of GLIM Criteria in Patients With Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the digestive tract that frequently lead to malnutrition.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative (UC), Malnutrition
- Trial name
- NCT07888023
- Volunteers
- 210 people
- Sponsor
- Assiut University
Colitis, Ulcerative
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether BMS-936557 is effective in the treatment of moderate to severely active ulcerative colitis in patients who have had insufficient response and/or intolerance to other medical…
- Trial name
- NCT01294410
- Testing
- Anti-IP-10 Antibody
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 305 people
- Sponsor
- Bristol-Myers Squibb